Skip to main content
SpringerLink
Log in

Inhibition of Eukaryotic Initiating Factor eIF4E Overcomes Abemaciclib Resistance in Gastric Cancer

  • Original Article
  • Published:
Current Medical Science Aims and scope Submit manuscript

Abstract

Objective

Aberrant activating mutations in cyclin-dependent kinases 4 and 6 (CDK4/6) are common in various cancers, including gastroesophageal malignancies. Although CDK4/6 inhibitors, such as abemaciclib and palbociclib, have been approved for breast cancer treatment, their effectiveness as a monotherapy remains limited for gastroesophageal tumors. The present study explored the underlying mechanism of abemaciclib resistance.

Methods

Abemaciclib-resistant gastric cancer cell lines were generated, and the phospho-eukaryotic translation initiation factor 4E (p-eIF4E) and eIF4E expression was compared between resistant and parental cell lines. In order to analyze the role of eIF4E in cell resistance, siRNA knockdown was employed. The effectiveness of ribavirin alone and its combination with abemaciclib was evaluated in the gastric cancer xenograft mouse model.

Results

The upregulation of eIF4E was a common feature in gastric cancer cells exposed to prolonged abemaciclib treatment. Gastric cancer cells with increased eIF4E levels exhibited a better response to eIF4E inhibition, especially those that were resistant to abemaciclib. Ribavirin, which is an approved anti-viral drug, significantly improved the efficacy of abemaciclib, both in vitro and in vivo, by inhibiting eIF4E. Importantly, ribavirin effectively suppressed the abemaciclib-resistant gastric cancer growth in mice without causing toxicity.

Conclusion

These findings suggest that targeting eIF4E can enhance the abemaciclib treatment for gastric cancer, proposing the potential combination therapy of CDK4/6 inhibitors with ribavirin for advanced gastric cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018,68(6):394–424

    Article  PubMed  Google Scholar 

  2. Sexton RE, Al Hallak MN, Diab M, et al. Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer Metastasis Rev, 2020,39(4):1179–1203

    Article  PubMed  PubMed Central  Google Scholar 

  3. Chia NY, Tan P. Molecular classification of gastric cancer. Ann Oncol, 2016,27(5):763–769

    Article  PubMed  Google Scholar 

  4. Machlowska J, Baj J, Sitarz M, et al. Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies. Int J Mol Sci, 2020,21(11):1–20

    Article  Google Scholar 

  5. Schettini F, De Santo I, Rea CG, et al. CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. Front Oncol, 2018,8:608

    Article  PubMed  PubMed Central  Google Scholar 

  6. Migliaccio I, Di Leo A, Malorni L. Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy. Curr Opin Oncol, 2014,26(6):568–575

    Article  CAS  PubMed  Google Scholar 

  7. Mikhail S, Albanese C, Pishvaian MJ. Cyclin-dependent kinase inhibitors and the treatment of gastrointestinal cancers. Am J Pathol, 2015,185(5):1185–1197

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Karasic TB, O’Hara MH, Teitelbaum UR, et al. Phase II Trial of Palbociclib in Patients with Advanced Esophageal or Gastric Cancer. Oncologist, 2020,25(12):e1864–e1868

    Article  CAS  PubMed  Google Scholar 

  9. Romagnoli A, D’Agostino M, Ardiccioni C, et al. Control of the eIF4E activity: structural insights and pharmacological implications. Cell Mol Life Sci, 2021,78(21–22):6869–6885

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Larsson O, Li S, Issaenko OA, et al. Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors. Cancer Res, 2007,67(14):6814–6824

    Article  CAS  PubMed  Google Scholar 

  11. Zheng J, Li X, Zhang C, et al. eIF4E Overexpression Is Associated with Poor Prognoses of Ovarian Cancer. Anal Cell Pathol (Amst), 2020,2020:8984526

    PubMed  Google Scholar 

  12. Lu J, Zang H, Zheng H, et al. Overexpression of p-Akt, p-mTOR and p-eIF4E proteins associates with metastasis and unfavorable prognosis in non-small cell lung cancer. PLoS One, 2020,15(2):e0227768

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Xu T, Zong Y, Peng L, et al. Overexpression of eIF4E in colorectal cancer patients is associated with liver metastasis. Onco Targets Ther, 2016,9:815–822

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Martinez-Saez E, Peg V, Ortega-Aznar A, et al. peIF4E as an independent prognostic factor and a potential therapeutic target in diffuse infiltrating astrocytomas. Cancer Med, 2016,5(9):2501–2512

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Ge Y, Wu Q, Ma G, et al. Hypermethylation of EIF4E promoter is associated with early onset of gastric cancer. Carcinogenesis, 2018,39(1):66–71

    Article  CAS  PubMed  Google Scholar 

  16. Tapia O, Riquelme I, Leal P, et al. The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance. Virchows Arch, 2014,465(1):25–33

    Article  CAS  PubMed  Google Scholar 

  17. Chen CN, Hsieh FJ, Cheng YM, et al. Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome. J Surg Oncol, 2004,86(1):22–27

    Article  CAS  PubMed  Google Scholar 

  18. Liang S, Guo R, Zhang Z, et al. Upregulation of the eIF4E signaling pathway contributes to the progression of gastric cancer, and targeting eIF4E by perifosine inhibits cell growth. Oncol Rep, 2013,29(6):2422–2430

    Article  CAS  PubMed  Google Scholar 

  19. Graff JR, Konicek BW, Carter JH, et al. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res, 2008,68(3):631–634

    Article  CAS  PubMed  Google Scholar 

  20. Hu K, Zhang J, Yu M, et al. Inhibition of Mnk-eIF4E pathway sensitizes the efficacy to chemotherapy in anaplastic thyroid cancer. Future Oncol, 2017,13(6):489–498

    Article  CAS  PubMed  Google Scholar 

  21. Grzmil M, Seebacher J, Hess D, et al. Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy. Cell Signal, 2016,28(9):1412–1421

    Article  CAS  PubMed  Google Scholar 

  22. Borden KL, Culjkovic-Kraljacic B. Ribavirin as an anticancer therapy: acute myeloid leukemia and beyond? Leuk Lymphoma, 2010,51(10):1805–1815

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res, 2010,70(2):440–446

    Article  CAS  PubMed  Google Scholar 

  24. Culjkovic-Kraljacic B, Fernando TM, Marullo R, et al. Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. Blood, 2016,127(7):858–868

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Liu Y, Zhao Y, Han C, et al. Expression of CDK6 in Stomach Cancer and the Effect of CDK4/6 Inhibitor PD-0332991 on the Function of Stomach Cancer Cells. Comput Math Methods Med, 2022,2022:2402567

    PubMed  PubMed Central  Google Scholar 

  26. Valenzuela CA, Vargas L, Martinez V, et al. Palbociclib-induced autophagy and senescence in gastric cancer cells. Exp Cell Res, 2017,360(2):390–396

    Article  CAS  PubMed  Google Scholar 

  27. Bae HJ, Kang SK, Kwon WS, et al. p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancer. Biochem Pharmacol, 2021,183:114320

    Article  CAS  PubMed  Google Scholar 

  28. Min A, Kim JE, Kim YJ, et al. Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells. Cancer Lett, 2018,430:123–132

    Article  CAS  PubMed  Google Scholar 

  29. Zhang Y, He LJ, Huang LL, et al. Oncogenic PAX6 elicits CDK4/6 inhibitor resistance by epigenetically inactivating the LATS2-Hippo signaling pathway. Clin Transl Med, 2021,11(8):e503

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Zhu Y, Wang C, Li M, et al. Targeting of MNK/eIF4E overcomes chemoresistance in cervical cancer. J Pharm Pharmacol, 2021,73(10):1418–1426

    Article  PubMed  Google Scholar 

  31. Liu T, Li R, Zhao H, et al. eIF4E promotes tumorigenesis and modulates chemosensitivity to cisplatin in esophageal squamous cell carcinoma. Oncotarget, 2016,7(41):66851–66864

    Article  PubMed  PubMed Central  Google Scholar 

  32. Fischer PD, Papadopoulos E, Dempersmier JM, et al. A biphenyl inhibitor of eIF4E targeting an internal binding site enables the design of cell-permeable PROTAC-degraders. Eur J Med Chem, 2021,219:113435

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Volpon L, Osborne MJ, Borden KLB. Biochemical and Structural Insights into the Eukaryotic Translation Initiation Factor eIF4E. Curr Protein Peptide Sci, 2019,20(6):525–535

    Article  CAS  Google Scholar 

  34. Kentsis A, Topisirovic I, Culjkovic B, et al. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci USA, 2004,101(52):18105–18110

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Pettersson F, Yau C, Dobocan MC, et al. Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer. Clin Cancer Res, 2011,17(9):2874–2884

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Bodenheimer HC Jr, Lindsay KL, Davis GL, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology, 1997,26(2):473–477

    Article  CAS  PubMed  Google Scholar 

  37. Assouline S, Culjkovic B, Cocolakis E, et al. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood, 2009,114(2):257–260

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Renmin Hospital, Hubei University of Medicine, Shiyan, 442000, China

    Huo-long Zha, Wei Shi & Ying-ying Liao

  2. Department of Critical Care Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, China

    Wei Chen

Authors
  1. Huo-long Zha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wei Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wei Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ying-ying Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Wei Shi or Ying-ying Liao.

Ethics declarations

The authors declare that they have no competing interests.

Additional information

This work was supported by the Nature Science Foundation of Hubei Province (No. 2017CFB606).

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zha, Hl., Chen, W., Shi, W. et al. Inhibition of Eukaryotic Initiating Factor eIF4E Overcomes Abemaciclib Resistance in Gastric Cancer. CURR MED SCI 43, 927–934 (2023). https://doi.org/10.1007/s11596-023-2789-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-023-2789-3

Key words

Search

Navigation